scholarly journals Early Prediction of Objective Response of Fibrinogen in a Real-World Cohort of Hepatocellular Carcinoma Cases Treated by Programmed Cell Death Receptor-1 and Lenvatinib

2021 ◽  
Vol Volume 14 ◽  
pp. 5019-5026
Author(s):  
Yanjun Shen ◽  
Huige Wang ◽  
Jianying Wei ◽  
Wendong Li
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Real World ◽  
Objective Response ◽  
Death Receptor ◽  
Early Prediction ◽  
Cell Death Receptor

scholarly journals A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China

2021 ◽  
Vol 11 ◽  
Author(s):  
Sihui Zhu ◽  
Chenxi Liu ◽  
Yanbing Dong ◽  
Jie Shao ◽  
Baorui Liu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cell Death ◽  
Liver Cancer ◽  
Programmed Cell Death ◽  
Intrahepatic Cholangiocarcinoma ◽  
Real World ◽  
Liver Tumors ◽  
Chinese Patients ◽  
First Line ◽  
Cell Death Protein

Lenvatinib has been ratified as a first-line medication for advanced liver tumors by the American Food and Drug Administration. To assess the effectiveness and security of Lenvatinib in the Chinese population in a real-world setting, we enrolled 48 patients with unresectable liver cancer, managed from December 2018 to March 2021. Among them, 9 and 39 (83.30% men) patients had intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC), respectively. Twenty-one (43.75%) patients had progressive disease after first-line treatment, and others (56.25%) had not receiving systemic treatment. Lenvatinib was administered alone or in combination with a programmed cell death protein 1 antibody (anti-PD-1). Treatment duration, median progression-free survival (mPFS), and median overall survival (mOS) were examined. The mOS and mPFS were 22.43 and 8.93 months, respectively. Of HCC patients treated with Lenvatinib only, the mOS and mPFS were 22.43 and 11.60 months, respectively. The corresponding values for HCC cases managed with anti-PD-1 combined with Lenvatinib were 21.77 and 7.10 months, respectively. ICC patients did not reach the mOS and their mPFS was 8.63 months. The present findings support the efficacy and security of Lenvatinib in the real-world therapy of Chinese patients with unresectable liver cancer.

Novel anti-inflammatory mechanism in critically ill: Soluble programmed cell death receptor-1 (sPD-1)

2011 ◽  
Vol 213 (3) ◽  
pp. S54-S55
Author(s):  
Sean F. Monaghan ◽  
Rajan K. Thakkar ◽  
Chun S. Chung ◽  
Yaping Chen ◽  
Daithi S. Heffernan ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Critically Ill ◽  
Death Receptor ◽  
Inflammatory Mechanism ◽  
Anti Inflammatory ◽  
Cell Death Receptor

scholarly journals Sepsis-Induced Potentiation of Peritoneal Macrophage Migration Is Mitigated by Programmed Cell Death Receptor-1 Gene Deficiency

2013 ◽  
Vol 6 (3) ◽  
pp. 325-338 ◽  
Author(s):  
Alfred Ayala ◽  
Gwendolyn F. Elphick ◽  
Ye Sul Kim ◽  
Xin Huang ◽  
Arnaldo Carreira-Rosario ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Peritoneal Macrophage ◽  
Death Receptor ◽  
Macrophage Migration ◽  
Gene Deficiency ◽  
Cell Death Receptor

scholarly journals A Novel Role for Programmed Cell Death Receptor Ligand-1 in Sepsis-Induced Intestinal Dysfunction

2016 ◽  
Vol 22 (1) ◽  
pp. 830-840 ◽  
Author(s):  
Youping Wu ◽  
Chun-Shiang Chung ◽  
Yaping Chen ◽  
Sean Farrell Monaghan ◽  
Sima Patel ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Death Receptor ◽  
Receptor Ligand ◽  
Death Receptor Ligand ◽  
Cell Death Receptor
Sign in / Sign up

Export Citation Format

Share Document